The 2016–2017 ECDC point prevalence survey was the second EU-wide point prevalence survey of healthcare-associated infections and antimicrobial use in acute care hospitals.
This report is based on data for 2018-2020 retrieved on 13 February 2023 from The European Surveillance System (TESSy) and ECDC’s decentralised data storage for antimicrobial resistance and healthcare-associated infections (ARHAI). TESSy is a system for the collection, analysis and dissemination of data on communicable diseases.
The results presented in this report are based on antimicrobial resistance (AMR) data from invasive isolates reported to the Central Asian and European surveillance of Antimicrobial Resistance (CAESAR) network and the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2022 (data referring to 2021).
This literature review, covering the period from 2000 to January 2022, assessed the state of knowledge on biocide resistance in wild vector populations across the EU/EEA and neighbouring countries.
In 2016–2017, the European Centre for Disease Prevention and Control (ECDC) organised the third point prevalence survey (PPS) of healthcare-associated infections (HAIs) and antimicrobial use in European long-term care facilities (LTCFs) or HALT-3.
This report covers the events and threats detected by the ECDC epidemic intelligence (EI) team in 2020 and the actions taken in relation to these findings. The objective of EI at ECDC is to rapidly detect and assess public health events of any origin to ensure EU health security as defined in ECDC’s mandate.
For 2021, 29 countries (27 European Union (EU) Member States and two European Economic Area (EEA) countries – Iceland and Norway) reported data on antimicrobial consumption.
Twenty-nine European Union/European Economic Area (EU/EEA) countries reported cases of pathogens with antimicrobial resistance (AMR) to the European Antimicrobial Resistance Surveillance Network (EARS-Net) for 2021, based on data for invasive bacterial isolates (i.e. retrieved from blood or cerebrospinal fluid).
The results presented in this executive summary are based on antimicrobial resistance (AMR) data from invasive isolates reported to the Central Asian and European Surveillance of Antimicrobial Resistance (CAESAR) network and the European Antimicrobial Resistance Surveillance Network (EARS-Net) in 2022 (data referring to 2021).